Squamous cell carcinoma - Laphámsejtes Karcinóma
☆ A 2022-es németországi Stiftung Warentest eredményei szerint a fogyasztók elégedettsége a ModelDermmel csak valamivel volt alacsonyabb, mint a fizetős távorvoslási konzultációkkal.
Squamous cell carcinoma well differentiated ― Egy szomszédos aktinikus keratosis figyelhető meg.
References
A Squamous cell carcinoma (SCC) a második leggyakoribb bőrrák az Egyesült Államokban basal cell carcinoma után. Általában a actinic keratosis nevű rákmegelőző elváltozásokból indul ki, és átterjedhet a test más részeire is. A fő ok a nap ultraibolya (UV) sugárzása, amely idővel felhalmozódik. A kezelés általában sebészeti eltávolítást foglal magában, különösen a fej és a nyak SCC esetében. A sugárterápia lehetőség az idősebb betegek vagy azok számára, akik nem tudnak műtétet végezni. Az immunszuppresszió növeli az SCC kockázatát. Bár ritka, az SCC terjedhet, különösen a legyengült immunrendszerű betegeknél. Az SCC-ben szenvedők számára fontos a rendszeres ellenőrzés és a fényvédelem.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
A Cutaneous squamous cell carcinoma (CSCC) a második leggyakoribb rák az emberekben, és száma egyre növekszik. Bár a CSCC általában jóindulatú klinikai viselkedést mutat, lokálisan és a test más részeire is átterjedhet. A tudósok a CSCC fejlesztésében szerepet játszó specifikus útvonalakat azonosítottak, amelyek új kezelésekhez vezetnek. A mutációk magas száma és az immunszupprimált betegek fokozott kockázata késztette az immunterápia kidolgozását. Ez az áttekintés a CSCC genetikai gyökereit, valamint a specifikus molekulákat és az immunrendszert célzó legújabb kezeléseket vizsgálja.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnosztika és kezelés
#Dermoscopy
#Skin biopsy